PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock

Press/Media

Period	2 Mar 2022

Media coverage

Title	PURIFY Investigators Announce First Patient Enrolled in a US Randomized Controlled IDE Trial Evaluating Seraph 100 for the Treatment of Septic Shock
Media name/outlet	BioSpace
Country/Territory	United States
Date	2/03/22
URL	https://www.biospace.com/article/releases/purify-investigators-announce-first-patient-enrolled-in-a-us-randomized-controlled-ide-trial-evaluating-seraph-100-for-the-treatment-of-septic-shock/?s=105
Persons	Kevin Chung